Low-dose radiation and immunotherapy to shrink hard-to-remove esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment approach that combines low-dose radiation with immunotherapy and chemotherapy for people with esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough to make surgery possible, which could improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal squamous cell carcinoma (a type of esophageal cancer) that is considered borderline resectable or unresectable, meaning surgery is not straightforward.
- You have not had any previous cancer treatment like chemotherapy, radiation, or immunotherapy.
- Your cancer has not spread to distant organs (except possibly to the lymph nodes above the collarbone).
- You are in generally good health (able to care for yourself, no serious heart or lung problems).
- Your blood and organ function tests are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, and low-dose radiation for people with esophageal cancer that did not shrink after initial chemotherapy and immunotherapy. The goal is to see if this new combination can help control the cancer before surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
Hear when a new Immune Checkpoint Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.